MYC and lymphoma: We therefore decided to evaluate the effectiveness of a PAK inhibitor, PF-3758309 which has already been reported to be efficacious in models of T-cell leukaemia/lymphoma [59] in vivo, by analysing its effect on the growth of three transplanted WT Eμ-Myc and Eμ-Myc/RelAT505A tumours.